![]() | ![]() |
Formats:
|
||||||||||||||
Copyright © 2002, Cold Spring Harbor Laboratory Press Highly Efficient Modification of Bacterial Artificial Chromosomes (BACs) Using Novel Shuttle Vectors Containing the R6Kγ Origin of Replication 1Laboratory of Molecular Biology, 2Gensat project, 3Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10021, USA 4Corresponding author. Received May 30, 2002; Accepted September 30, 2002. This article has been cited by other articles in PMC.Abstract Bacterial artificial chromosome (BAC) mediated transgenesis has proven to be a highly reliable way to obtain accurate transgene expression for in vivo studies of gene expression and function. A rate-limiting step in use of this technology to characterize large numbers of genes has been the process with which BACs can be modified by homologous recombination in Escherichia coli. We report here a highly efficient method for modifying BACs by using a novel set of shuttle vectors that contain the R6Kγ origin for DNA replication, the E. coli RecA gene for recombination, and the SacB gene for negative selection. These new vectors greatly increased the ease with which one can clone the shuttle vectors, as well as screen for co-integrated and resolved clones. Furthermore, we simplify the shuttle vector cloning to one step by incorporation of a “built-in” resolution cassette for rapid removal of the unwanted vector sequences. This new system has been used to modify a dozen BACs. It is well suited for efficient production of modified BACs for use in a variety of in vivo studies. Bacterial artificial chromosomes (BACs) and P-1 derived artificial chromosomes (PACs) have several advantages over the traditional large DNA cloning system, the yeast artificial chromosomes (YACs). These include large carrying capacity (~100–300 kb), high clonal stability, low rate of chimerism, and the ease with which they can be handled ( Shizuya et al. 1992; Ioannou et al. 1994; Marra et al. 1997; Kelley et al. 1999). BACs have served as the primary source of archived genomic DNA for a variety of genome mapping and sequencing projects (Mozo et al. 1999; Hoskins et al. 2000; Osoegawa et al. 2000; McPherson et al. 2001). Indeed, physical contigs are now available for the entire human genome and the mouse genome, as well as a variety of other experimental organisms (Mozo et al. 1999; Hoskins et al. 2000; Osoegawa et al. 2000; McPherson et al. 2001). Transgenic mice are important tools for in vivo genetic studies. The conventional transgenic constructs with <20 kb of the genomic sequence often result in strong position effects, leading to lack of expression or incorrect expression. Because the genomic DNA inserts in BACs are sufficiently large in most instances to carry an entire transcription unit and its associated regulatory regions, BACs can be used for a variety of functional studies that could not be accomplished by using conventional transgenic approaches. An important advance in the use of BACs for functional studies came with the development of methods for precise manipulation (i.e., marker/gene insertion, deletion, point mutation, etc.) of the genomic DNA carried in the BAC (Yang et al. 1997). This ability to manipulate BAC constructs made possible strategies for gene expression and function studies, as well as cell marking and isolation experiments, that had previously been widely used only in invertebrate systems (Heintz 2001). The first and, so far, most widely used method (Yang et al. 1997) for manipulation of BAC DNA relies on a temperature-sensitive pSV1.RecA shuttle vector carrying the Escherichia coli RecA gene, which restores to the recombination-deficient BAC host the ability to undergo the homologous recombination steps required to generate precise modifications at a desired position within the genomic DNA insert. This system has been successfully applied to generate a series of murine BAC transgenes with accurate expression of marker genes in vivo, including Zipro1 (Yang et al. 1997, 1999), Calbindin (X.W. Yang, W. Jiang, and N. Heintz, unpubl.), Acha9 (Zuo et al. 1999), Rag1 and Rag2 (Yu et al. 1999a,b), Renin-1 (Mullins et al. 2000), NPY (DeFalco et al. 2001), Myf4/Myf5 (Carvajal et al. 2001), P57 (Kip2) (John et al. 2001a), and Neuronatin (John et al. 2001b). Several other systems for BAC modification protocols have subsequently been developed, by using transient introduction of RecE/T or λ Red and Gam genes to achieve proper targeting of the desired modification within the BAC ( Jessen et al. 1998; Zhang et al. 1998; Imam et al. 2000; Lee et al. 2001). Here we report a novel RecA-based system for BAC modification that is simple, highly efficient, and suitable for large-scale studies. This system relies on a new shuttle vector containing an E. coli replication origin (R6kγ) that can not replicate in the BAC host strain DH10B (Filutowicz and Rakowski 1998), a RecA gene to support homologous recombination, and a highly efficient negative selectable marker (sacB) to enhance the removal of unwanted vector sequences from the manipulated BAC. By using this new BAC modification method, we have prepared BAC transgenic constructs for a dozen central nervous system (CNS) expressed genes. This new BAC modification method can be readily applied for large-scale studies of gene expression and function in vivo. RESULTS An Improved Shuttle Vector for BAC Modification Based on the R6kγ Origin of ReplicationBAC libraries are maintained in the RecA− bacterial strain (DH10B), which is deficient in homologous recombination (Schizuya et al. 1992). The first step in manipulating BACs involves restoration of the competence for homologous recombination by introduction into the host cell of an enzyme or enzymes that can complement its deficiency for homologous recombination, and selection against freely replicating shuttle vector to identify cells in which the shuttle vector had co-integrated into the BAC by homologous recombination. In our original BAC modification system, the temperature-sensitive pSV1.RecA shuttle vector may replicate in the BAC host cells at a low level to generate a background of false positives, which may reduce the co-integration efficiency (defined as the number of correct co-integrates among the total number of colonies tested). To search for vectors that are simple to be manipulated and can achieve high efficiency of BAC modification, we tested the pLD53 vector described by Metcalf et al. (1996). This vector contains an R6kγ origin of replication, which is absolutely dependent on the π protein encoded by the pir gene for replication (Filutowicz et al. 1998). It can be grown at relatively high copy number in pir+ cells (such as the Pir2 cells from Invitrogen) to obtain sufficient DNA for cloning. Because the BAC host cells are pir−, this vector can not freely replicate in these cells and therefore could confer very lower background. We hypothesized that a shuttle vector containing the R6kγ origin, the RecA gene and a recombination cassette (Fig. (Fig.1A),1
To test this strategy, we constructed a shuttle vector based on pLD53 (Metcalf et al. 1996) that carried the E. coli RecA gene, an IRES.EGFP marker gene, and a 500-bp homology arm “A” corresponding to the last exon of the Zipro1 gene (Yang et al. 1999), as shown in Figure Figure1.1 The Use of pLD53.RecA Vectors for the Two-Step BAC ModificationOur original pSV1.RecA-based BAC modification system uses the two steps of homologous recombination—a co-integration step, which results in complete integration of the shuttle vector into the BAC, and a resolution step, which results in excision and subsequent loss of the shuttle vector and precise placement of intended modification in the chosen site on the BAC (Yang et al. 1997). Such a two-step modification protocol is highly desirable for transgenic studies because it results in precise modification of the BAC without leaving any unwanted sequences behind, unlike the RecET- or λ Red–based modification protocols in which at least an extra LoxP site or an extra FRT site is left behind in the modified BAC (Zhang et al. 1998; Lee et al. 2001). These extra sequences may limit one's option of using Cre or Flp recombinase in further genetic manipulations of these BAC transgenic mice. In order to perform the two-step BAC modification, we designed the pLD53.SC-AB shuttle vector (Fig. (Fig.2A).2
The outline for the two-step protocol of BAC modification incorporating these features is diagramed in Figure Figure2A.2 Another optional screening step can be incorporated into the protocol to maximize the recovery of the correctly resolved BACs. Because resolved BACs have lost the shuttle vector carrying the SacB, RecA, and Amp genes, higher resolution efficiency can be achieved by adding a screen for the loss of the RecA gene and/or the loss of the Amp gene. The loss of RecA gene confers resistance to UV light (Rupp et al. 1971). Those colonies that are UV sensitive (RecA−) and/or Amp sensitive are chosen from the master plate for further analysis. This simple added screen improves the recovery of the desired resolved products to >80% in the majority of cases. By using the pLD53 SC-AB plasmid, we have modified two different human BACs containing the 170-kb Huntingtin gene. In three separate modifications, we have inserted two different disease-causing mutations, one encoding 103 glutamine repeats and another encoding 260 glutamine repeats into the Huntingtin BACs. In all cases, the co-integration efficiency was between 15% and 50%, and the resolution efficiency was between 27% and 100% (Table 1; Fig. Fig.2B).2
The Use of a “Built-In” Resolution Cassette for Two-Step BAC ModificationTo further simplify the shuttle vector cloning process, we next developed an improved strategy for shuttle vector preparation based on a “built-in” resolution cassette. The logic for this design was that if we provide two copies of the marker gene cassette (i.e., IRES.EGFP or EGFP alone) properly positioned in the shuttle vector, those duplicate copies can be used for highly efficient removal of the vector sequences during the resolution step of BAC modification (Fig. (Fig.3).3
The built-in resolution strategy also results in very high co-integration and resolution efficiency. We have modified six different CNS-expressed genes (BF1, pro-Cadherin, Leap1, RORa, RORb, Zipro1). As shown in Figure Figure44
DISCUSSION BACs are important large insert vectors used widely in positional cloning studies (Shizuya et al. 1992; Osoegawa et al. 2000). The ability to modify BACs for transgenic studies enables BACs to be used increasingly in functional studies (Heintz 2001). Although several different methodologies are now available for manipulating BACs by homologous recombination, the current study represents a significant improvement on the simplicity and efficiency of the RecA-based BAC modification system. A major finding of the current study is that the R6kγ-based shuttle vectors, although they can not replicate in the BAC host bacteria, can express sufficient RecA protein to support efficient co-integration of the shuttle vector. Several features of the current R6kγ vector-based shuttle vectors enable the significant improvement in the RecA-based BAC modification process. First, these plasmids can readily be manipulated in pir(+) bacteria in terms of cloning and DNA preparation. Second, because the nonintegrated shuttle vector plasmids could not replicate at all in the BAC host, they are lost automatically. This obviates the need for temperature shifting in the original modification system. Third, the SacB gene as a negative selection marker gene also has advantages over the Tet gene: It significantly simplifies the plate preparation step (much fewer ingredients in the sucrose plates than in the fusaric acid plates) and shortens the incubation time from 3 d to overnight. Fourth, the use of UV and/or Amp selection can further increase the resolution efficiency. Finally, the current system enables one to perform colony PCR to identify with high reliability both the co-integrates or resolved BACs. Such colony PCR with the pSV1.RecA system may produce false positives owing to the low persistence of the free shuttle vectors. Therefore, in the current protocol, no DNA preparation is necessary during the modification process. Overall, the current BAC modification system greatly shortens the total time needed for each modification cycle, and one may be able to modify multiple BACs during each cycle. Our data documented that a single investigator can easily use the built-in resolution cassette system to manipulate up to six different BACs simultaneously in each cycle, and each cycle usually takes ~2 wk to complete. A highly efficient method for BAC modification allows one to fully explore the advantage of the BAC system for functional studies in the postgenomic era (Magdaleno et al. 1999; Heintz 2000). It is already clear that preparation of BAC transgenic mice can provide an important complement to other studies of gene expression and function such as gene targeting (Magdaleno et al. 1999; Heintz 2000). With the completion of the human genome project and a variety of other genome projects (Adams et al. 2000; Arabidopsis Genome Initiative 2000; Lander et al 2001; Venter et al. 2001), and the increasing ease of identification of appropriate BACs from the existing databases (Mozo et al. 1999; Hoskins et al. 2000; Osoegawa et al. 2000; McPherson et al. 2001; Tao et al. 2001), we believe that the highly efficient BAC modification system presented here can be applied to in vivo large-scale BAC-based studies of gene expression and function. METHODS Genes Used for BAC ModificationThe accession nos. for genes used for modification are listed below: Zipro1/RU49, U41671; BF1, U36760; Pro-cadherin, NM_007767; Leap1, AF220501; ROR α, NM_013646; ROR β, NM_006914; Smoothen, AF089721; Huntingtin, NM002111; and α-synuclein, NM007308. BACs were screened either with a PCR probe from the CITB mouse BAC library or with the RPCI-23 library (purchased from Research Genetics) by using standard protocol. Huntingtin and α-synuclein BACs were screened from the RPCI-11 human BAC libraries. Construction of the VectorsThe plasmids (pLD53.SC-AB and pLD53 SC1) are derived from the pLD53 (Metcalf et al. 1996). pLD53 was digested with BamHI and SacI to replace the tetAR and oriT origin with a NotI-SalI-SpeI adaptor. The building vector was based on the pBluescript SK vector (Stratagene). A 2.3-kb SalI-EcoRV fragment containing the SacB gene from Bacillus subtilis was cloned into SalI and EcoRV sites of the pBS.SK vector. A 1.7-kb BamHI fragment containing RecA from pSV1.RecA (Yang et al. 1997) was subcloned into BamHI site. For pLD53.SC-AB shuttle vector, this cassette was then cloned into NotI-SalI sites of the modified pLD53 vector. Besides the R6Kγ origin, the E. coli RecA gene, a SacB gene, and an Amp-resistant gene, this vector also has two unique cloning sites, AscI and NotI, for the subcloning of the “A” and “B” homology arms. For pLD53-SC1, besides the SacB gene and RecA gene, a SpeI fragment of IRESEGFP was further cloned into SpeI site of pBluescript SK, and a second IRESEGFP was cloned into AscI site located upstream of the first IRESEGFP; the 5′ end AscI site was knocked out. A PGK.poly A fragment with 3′ end AscI-NotI-SwaI-SmaI multiple cloning site was then cloned into AscI and SmaI sites located upstream of the first IRESEGFP. The whole recombination cassette was then cloned into NotI-SalI sites of the modified pLD53 vector. This shuttle vector was digested with Asc/Sma1 to subclone the 300- to 500-bp “A-box” fragment, which was PCR amplified and digested with AscI before cloning. Preparation of the Competent Cells for Electroporation and Selection for Co-integratesOvernight culture of BAC host bacterial was diluted 1000-fold in 100 mL of LB medium supplemented with Chlor (12.5μg/mL), grown to an OD600 of 0.7–0.8, and chilled on ice for 15 min. Bacteria were collected by centrifugation at 3000 rpm for 10 min at 4°C and resuspended in equal volume of ice-cold 10% glycerol. This step was repeated twice, and the bacteria pellet was resuspended in 400 μL of ice-cold 10% glycerol. Aliquots were stored in −80°C. Before the electroporation, cells were thawed on ice, and 2μL of DNA (0.5μg/μL) was added. Electroporation was performed using BioRad Gene Pulser II and ice-cold cuvettes as follows: 40 μL of competent cells were mixed with 2 μL of plasmid DNA (0.5μg/mL) on ice for 1 min. DNA and cells were transferred to a cold 0.1-cm cuvette. Electroporation conditions were 25 μF, 1.8 kV, and 200 Ω. After electroporation, 1 mL of SOC was immediately added to the cuvette, and the contents were then transferred to a 17 × 100-mm polypropylene tube. After recovery for 1 h at 37°C with shaking, the cells were selected in LB medium containing proper antibiotics for overnight. Then the culture was diluted 1:1000 and incubated for ~14 h at 37°C. This culture was further diluted 1:5000 and incubated for ~8 h at 37°C. Then, cells were diluted and spread onto LB plates containing Chlor (12.5 μg/mL) and Amp (50 μg/mL). Individual colonies were picked to analyze for presence of co-integrates.Identification and Characterization of Co-integrates and Resolved BACsFirst, the co-integrates were identified by double selection for Chlor (12.5 μg/mL) and Amp (50 μg/mL). Selected colonies were picked, grown in 3 mL of LB containing Chlor and Amp and were characterized by PCR or Southern blot analysis. DNA was prepared and digested with SpeI. Correct co-integrates were identified by Southern blot by using “A box” as a hybridization probe. Identification and Characterization of Resolved BACsOnce the co-integrates were identified, two positive colonies were picked from the Chlor/Amp plates, inoculated with 5mL of LB supplemented with Chlor (12.5μg/mL) and 5%–6% sucrose, and incubated for 8 h at 37°C for CITB-BACs and for 1 h for RPCI23-BACs. Culture was diluted 1:5000, spread onto LB plates containing Chlor (12.5μg/mL) and 5%–6% sucrose, and incubated overnight at 37°C. To enhance the resolution efficiency, exposure to UV light may be used as a selection step. Colonies were picked and plated on two agar plates: The master plate was incubated at 37°C directly; the other plate was exposed with UV light for 30 sec and incubated at 37°C. UV-sensitive colonies (hence, RecA−) were picked from the master plate and inoculated with 3 mL of LB supplemented with Chlor (12.5μg/mL) only. The resolved BACs were screened by PCR or Southern blot. Acknowledgments We thank Barry Wanner for kindly providing the pLD53 vector; Hong Zhu, Sanjay Mehta, Cuidong Wong, Tom Sung, Jie Xin, and Wendy Lee for technical assistance; Zhenyu Yue for helpful discussions and critical reading of the manuscript; and Judy Walsh for preparation of the manuscript. S.C. Gong and N. Heintz are supported by NIH grant PHS NO1-NS0233 and PHS NS 39636-03. N. Heintz is also supported by the Howard Hughes Medical Institute. X.W. Yang and C.J. Li are supported by a grant from the Cure Huntington Disease Initiative of the Hereditary Disease Foundation. The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact. Footnotes E-MAIL Heintz/at/rockvax.rockefeller.edu; FAX (212) 327-7878. Article and publication are at http://www.genome.org/cgi/doi/10.1101/gr.476202. REFERENCES
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||
Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8794-7.
[Proc Natl Acad Sci U S A. 1992]Nat Genet. 1994 Jan; 6(1):84-9.
[Nat Genet. 1994]Genome Res. 1997 Nov; 7(11):1072-84.
[Genome Res. 1997]Nucleic Acids Res. 1999 Mar 15; 27(6):1539-46.
[Nucleic Acids Res. 1999]Nat Genet. 1999 Jul; 22(3):271-5.
[Nat Genet. 1999]Nat Biotechnol. 1997 Sep; 15(9):859-65.
[Nat Biotechnol. 1997]Nat Rev Neurosci. 2001 Dec; 2(12):861-70.
[Nat Rev Neurosci. 2001]Nat Biotechnol. 1997 Sep; 15(9):859-65.
[Nat Biotechnol. 1997]Nat Genet. 1999 Aug; 22(4):327-35.
[Nat Genet. 1999]Proc Natl Acad Sci U S A. 1999 Nov 23; 96(24):14100-5.
[Proc Natl Acad Sci U S A. 1999]Science. 1999 Aug 13; 285(5430):1080-4.
[Science. 1999]Nature. 1999 Aug 12; 400(6745):682-7.
[Nature. 1999]Gene. 1998 Nov 26; 223(1-2):195-204.
[Gene. 1998]Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8794-7.
[Proc Natl Acad Sci U S A. 1992]Plasmid. 1996 Jan; 35(1):1-13.
[Plasmid. 1996]Gene. 1998 Nov 26; 223(1-2):195-204.
[Gene. 1998]Plasmid. 1996 Jan; 35(1):1-13.
[Plasmid. 1996]Nat Genet. 1999 Aug; 22(4):327-35.
[Nat Genet. 1999]Nat Biotechnol. 1997 Sep; 15(9):859-65.
[Nat Biotechnol. 1997]Nat Genet. 1998 Oct; 20(2):123-8.
[Nat Genet. 1998]Genomics. 2001 Apr 1; 73(1):56-65.
[Genomics. 2001]J Bacteriol. 1985 Nov; 164(2):918-21.
[J Bacteriol. 1985]J Mol Biol. 1971 Oct 14; 61(1):25-44.
[J Mol Biol. 1971]Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8794-7.
[Proc Natl Acad Sci U S A. 1992]Genome Res. 2000 Jan; 10(1):116-28.
[Genome Res. 2000]Nat Rev Neurosci. 2001 Dec; 2(12):861-70.
[Nat Rev Neurosci. 2001]Nat Genet. 1999 Aug; 22(4):319-20.
[Nat Genet. 1999]Hum Mol Genet. 2000 Apr 12; 9(6):937-43.
[Hum Mol Genet. 2000]Science. 2000 Mar 24; 287(5461):2185-95.
[Science. 2000]Nature. 2000 Dec 14; 408(6814):796-815.
[Nature. 2000]Nature. 2001 Feb 15; 409(6822):860-921.
[Nature. 2001]Plasmid. 1996 Jan; 35(1):1-13.
[Plasmid. 1996]Nat Biotechnol. 1997 Sep; 15(9):859-65.
[Nat Biotechnol. 1997]Nat Biotechnol. 1997 Sep; 15(9):859-65.
[Nat Biotechnol. 1997]Plasmid. 1996 Jan; 35(1):1-13.
[Plasmid. 1996]Plasmid. 1996 Jan; 35(1):1-13.
[Plasmid. 1996]